CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended April 30, 2024
CLOVER BIO-B: Form of Proxy for Use at Annual General Meeting
CLOVER BIO-B: (1). Proposed Grant of General Mandates to Repurchase Shares and to Issue New Shares; (2). Proposed Re-Election of the Retiring Directors; (3). Proposed Re-Appointment of Auditor; (4). Proposed Amendments to the Memorandum And Articles of Association; A
CLOVER BIO-B: Notice of Annual General Meeting
CLOVER BIO-B: 2023 Annual Report
CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT CLOVER ANNOUNCES POSITIVE PRELIMINARY PHASE I RESULTS FOR BIVALENT RSV VACCINE CANDIDATE SCB-1019 IN INITIAL YOUNG ADULT COHORT
CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended March 31, 2024
CLOVER BIO-B: GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
CLOVER BIO-B: DATE OF BOARD MEETING
CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended February 29, 2024
CLOVER BIO-B: Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
CLOVER BIO-B: Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended January 31, 2024
CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended December 31, 2023
CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT - CLOVER ANNOUNCES POSITIVE PHASE I RESULTS FOR SCB-219M FOR TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)
CLOVER BIO-B: GRANT OF EXTENSION OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14A.53 OF THE LISTING RULES UNDER THE LICENSE AGREEMENT
CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT - CLOVER INITIATES PHASE I CLINICAL TRIAL FOR RSV VACCINE CANDIDATE
CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended November 30, 2023
CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT - CLOVER COMPLETES BLA SUBMISSION FOR SEASONAL INFLUENZA VACCINE IN BRAZIL
No Data